New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 31, 2014
09:50 EDTMELAMELA Sciences enters $12.45M in private placement
MELA Sciences announced it has entered into definitive agreements with institutional investors and management for the private placement of $12.45M of the company’s convertible preferred stock, common stock warrants and common stock. The investors in the transaction were funds managed by Sabby Management, which comprise the company’s largest existing beneficial shareholder, and Broadfin Capital. In conjunction with the financing, MELA Sciences’ directors have agreed to purchase $150,000 in restricted common stock priced at 74c per share. MELA intends to use the net proceeds from the offering to re-launch MelaFind.
News For MELA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 23, 2015
09:14 EDTMELAOn The Fly: Pre-market Movers
Subscribe for More Information
08:43 EDTMELAMELA Sciences to host business news update conference call
Conference call to be held on June 23 at 8:30 am. Webcast Link
08:07 EDTMELAMELA Sciences acquires XTRAC, VTRAC business from PhotoMedex for $42.5M
MELA Sciences announced that it has signed and completed the purchase of the XTRAC and VTRAC Dermatology business from PhotoMedex, Inc. for $42.5M in cash and the assumption of certain business-related liabilities. The purchase price includes all of the accounts receivable, inventory and fixed and intangible assets of the businesses. To fund the purchase price of the transaction, the company has issued senior secured notes and convertible debentures equal to the transaction purchase price to certain investors. The XTRAC and VTRAC businesses generated $30.6M in revenues in 2014.
08:05 EDTMELAPhotoMedex sells XTRAC, VTRAC businesses to MELA for $42.5M in cash
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use